102 results
SD
EX-1.01
ABBV
Abbvie Inc
31 May 24
Conflict minerals disclosure
4:05pm
Strategy team that is led by Restricted Substances Management, supervised by the Vice President, Global Directs & Operations and includes stakeholder
8-K
EX-99.1
k2l1s7v g78cz9urpwmd
20 Feb 24
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
9:00am
8-K
EX-99.1
ejzcg5bgj g7
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
q3042h6cg3kii
29 Jun 23
Departure of Directors or Certain Officers
5:00pm
SD
EX-1.01
36jf9j uj6m4slxdsl
31 May 23
Conflict minerals disclosure
4:59pm
PX14A6G
owcmlw933zx9
4 May 23
Letter to shareholders
8:08am
PX14A6G
qm9 duaq6i762w3
11 Apr 23
Letter to shareholders
12:34pm
8-K
EX-99.1
avdwq1sr2nbt8uxjr4
17 Oct 22
Departure of Directors or Certain Officers
9:05am
SD
EX-1.01
jmnvbcn
31 May 22
Conflict minerals disclosure
5:01pm
PX14A6G
eo6h029hm
11 Apr 22
Letter to shareholders
4:35pm
PX14A6G
0zi1196 apr64x0ov
4 Apr 22
Letter to shareholders
8:36am
PX14A6G
6nwq4uq gs
30 Mar 22
Letter to shareholders
4:39pm